

Review Article

E3 Ubiquitin Ligases: Potential Therapeutic Targets for Skeletal Pathology and Degeneration

Ruiyin Zeng ^{1,2}, Yuan Xiong ^{1,2}, Ze Lin,^{1,2} Adriana C. Panayi,³ Yun Sun ^{2,4},
Faqi Cao ^{1,2} and Guohui Liu ^{1,2}

¹Department of Orthopaedics, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, China

²Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration, Wuhan 430022, China

³Division of Plastic Surgery, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA

⁴Department of Neurosurgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Correspondence should be addressed to Yun Sun; 627224540@qq.com, Faqi Cao; 13971293030@163.com, and Guohui Liu; liuguohui@hust.edu.cn

Received 20 April 2022; Revised 6 June 2022; Accepted 3 September 2022; Published 27 September 2022

Academic Editor: Ruoxian Deng

Copyright © 2022 Ruiyin Zeng et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

The ubiquitination-proteasome system (UPS) is crucial in regulating a variety of cellular processes including proliferation, differentiation, and survival. Ubiquitin protein ligase E3 is the most critical molecule in the UPS system. Dysregulation of the UPS system is associated with many conditions. Over the past few decades, there have been an increasing number of studies focusing on the UPS system and how it affects bone metabolism. Multiple E3 ubiquitin ligases have been found to mediate osteogenesis or osteolysis through a variety of pathways. In this review, we describe the mechanisms of UPS, especially E3 ubiquitin ligases on bone metabolism. To date, many E3 ubiquitin ligases have been found to regulate osteogenesis or osteoclast differentiation. We review the classification of these E3 enzymes and the mechanisms that influence upstream and downstream molecules and transduction pathways. Finally, this paper reviews the discovery of the relevant UPS inhibitors, drug molecules, and noncoding RNAs so far and prospects the future research and treatment.

1. Introduction

The ubiquitin-proteasome system (UPS) is comprised of several key components: ubiquitin (Ub), Ub-activating enzyme (E1), Ub-conjugating enzyme (E2), ubiquitin ligase (E3), deubiquitinating enzyme (DUB), and proteasome. UPS is an enzymatic cascade reaction that mediates the labeling of target proteins with ubiquitin tags, leading to their degradation via the proteasome pathway. The entire ubiquitination process can be briefly described as follows: Step 1: E1 activates ubiquitin and forms an E1-ubiquitin intermediate. This process requires the consumption of ATP. Step 2: ubiquitin is transferred from E1s to E2s, forming an E2-ubiquitin intermediate. Step 3: the E3s first recognize the target protein to be degraded and then recognize the

E2-ubiquitin intermediate, forming a complex containing the E2-ubiquitin intermediate, the E3s, and the target protein, and finally transfer the activated ubiquitin from E2s to the target protein. Step 4: the E2 enzyme and E3 enzyme are released from the complex, leaving the ubiquitin-tagged target protein. Step 5: the above process is repeated until multiple ubiquitin molecules are attached to the target protein to form a ubiquitin chain. Step 6: the ubiquitinated target protein is recognized and degraded into small fragments by the 26S proteasome. This process can be reversed by a group of proteases called the deubiquitinating enzymes (DUBs) which hydrolyze the peptide bond that links the target protein and ubiquitin [1].

During bone formation and reconstruction, osteogenic and osteoclastic activities need to be precisely coordinated

in order to maintain bone homeostasis. This is mainly mediated through three cell lineages: osteoblasts, osteoclasts, and osteocytes [2]. Osteoclasts differentiate from macrophages and monocytes in the human hematopoietic system and play essential roles in bone resorption [3]. Osteoblasts differentiate from mesenchymal stem cells (MSC) and synthesize, secrete, and mineralize bone matrix. Osteoblasts are the main functional cells in bone formation [4]. Osteocytes are the most common cells in mature bone tissue and are isolated from osteoblasts, which sense and transmit signals and secrete cytokines. These cells constitute the basic multicellular unit (BMU) that performs the bone reconstruction cycle [5]. Thus, the differentiation, function, and interaction of these cells are critical for regulating bone remodeling and maintaining bone homeostasis. E3 ubiquitin ligases have been found to influence osteoblasts and osteoclasts from a variety of mechanisms [6]. Therefore, regulating the relevant E3 ubiquitin ligases is an ideal approach for the treatment of the skeletal disorder.

In this review, we briefly describe the structure and function of the UPS, the mechanism of action of E3 ubiquitin ligases in bone metabolism regulation, and the E3 ubiquitin protein ligase inhibitors currently in use and molecules that are promising targets for future drug therapy.

2. Effect of E3 Ubiquitin Ligases in Skeletal Cell Fate and Pathology

E3 ubiquitin ligases can be classified into three major types based on their structures: the “really interesting new gene” (RING) family, the “homologous to E6-AP carboxyl terminus” (HECT) family, and the RING-between-RING-RING (RBR) family [7]. Different ligase domains can have specific ubiquitin transfer modes. For example, the RING E3s act as a scaffold that binds the E2 enzyme and substrate together, and ubiquitin is transferred directly from the E2s to the substrate without forming the E3-ubiquitin intermediate. However, in HECT E3s, an E3-ubiquitin intermediate is formed before ubiquitin is transferred to its substrate. More than 600 types of E3 ligases have been identified in the human genome, which contribute to the specificity of the UPS system [8].

Differentiation of the osteoblast lineage is regulated by a complex signaling pathway. Early osteoblast differentiation is mainly regulated by the BMP-SMAD-RUNX2 pathway. RUNX2 and its downstream molecule Osterix are the paramount osteoblast-specific transcription factors. This pathway triggers the expression of osteoblast phenotype genes and synthesizes bone matrix at a later stage [9]. In addition to this, Hedgehog, JNK, TGF- β , and classical Wnt/ β -catenin signaling pathways are associated with the development of osteoblasts [10]. Osteoblasts then embed in the bone matrix as osteocytes or die at the end of their fate [11]. Many E3 enzymes can regulate these pathways and in turn affect osteogenesis. For example, SMURF1 acts on multiple components of the BMP-SMAD-RUNX2 and MEKK2-JNK-JUNB pathways and inhibits osteogenesis. Cdh1 regulates the MEKK2 pathway to inhibit osteogenesis. SMURF2 downregulates the TGF- β pathway, thereby hindering the PI3-

kinase-AKT pathway activation, which in turn inhibits osteogenesis. WWP1 inhibits osteogenesis by promoting the degradation of SMAD4, RUNX2, and JUNB ubiquitination in osteoblasts. ITCH negatively regulates osteogenesis through JunB degradation. On the other hand, there are a number of E3 ubiquitinases that could promote osteogenesis. For example, TRIM16 reduces CHIP, therefore alleviates CHIP-mediated degradation of RUNX2, and then enhanced osteogenic. Besides, there are also proteins such as Cbl-b and c-Cbl that positively or negatively regulate bone formation by ubiquitinating the RTK-PI3K-AKT axis and other c-Cbl target proteins. In addition, insulin, through insulin-like growth factor-I (IGF-I), also affects the generation and differentiation of osteoblasts, while Cbl-b inhibits IGF-I-regulated osteogenic differentiation [12] (Table 1).

Osteoclasts are large multinucleated cells derived from the hematopoietic spectrum and regulated by several factors. Among them, the production of M-CSF and RANKL by bone marrow stromal cells and osteoblasts is essential in promoting osteoclastogenesis. M-CSF promotes the proliferation of osteoclast precursors, while RANKL stimulates the differentiation of osteoclast precursors to mature osteoclasts. In addition, the NF- κ B and Wnt/ β -catenin pathways also play an important role during osteoclast differentiation, which is regulated by E3 ubiquitin ligases [13]. For example, SMURF2 promotes osteoclastic differentiation by regulating RANKL expression; TRIM38 and CHIP negatively regulate NF- κ B and inhibit osteoclastic differentiation; RNF146 regulates the 3BP2/SRC pathway and Wnt/ β -catenin pathway and inhibits osteoclastic differentiation; LNX2 promotes activation of the NF- κ B and JNK pathways and downregulation of Notch pathway which enhances osteoclast differentiation (Table 1).

Following, we reviewed the detailed effects of a series of E3 ubiquitin ligases which have been found to regulate the differentiation of osteoblasts and osteoclasts.

2.1. SMURF1. SMURF1, which belongs to the Hect family of E3 ubiquitin ligases, interacts with BMP pathway-specific receptor-regulated SMADs to trigger their ubiquitination and degradation, thereby inactivating them. SMADs have three subgroups: receptor-activated SMADs (for example, SMAD1, -2, -3, -5, and -8), common SMADs (for example, SMAD4), and inhibitory SMADs (for example, SMAD6 and SMAD7) [14]. SMURF1 selectively interacts with BMP pathway-targeted SMAD1 and SMAD5 to induce their degradation, thus blocking BMP-SMAD-RUNX2 signal transduction [15]. In addition, SMURF1 and SMAD (SMAD6 or 7) inhibitors synergistically negatively regulate BMP by downregulating activated BMP receptors as well as receptors of R-SMADs [16]. A regulatory circuit exists between RUNX2 and the E3 ligase SMURF1. SMURF1 acts on the C-terminal PY motif of RUNX2 and mediates RUNX2 ubiquitination, while SMAD6 enhances SMURF1-induced RUNX2 degradation [17] and RUNX2 activates SMURF1 transcription in osteoblasts [18].

TGF- β 1 plays a multifaceted role in regulating osteoblast differentiation. In the early differentiation of osteoblast cells, TGF- β 1 promotes proliferation and differentiation through

TABLE 1: E3 ubiquitin ligases and bone metabolism.

Broad group of ligase	Name	Function	References
HECT	SMURF1	Inhibits osteoblast differentiation and mineralization	[15–23, 25, 26, 28–33]
HECT	SMURF2	Inhibits osteoblast differentiation; enhances osteoclast differentiation; inhibits angiogenesis; stimulates endochondral ossification	[34–39]
HECT	Nedd4-1	Enhances osteogenic differentiation	[62–64]
HECT	Nedd4-2	Inhibits osteoblast differentiation and mineralization	[65]
HECT	WWP1	Inhibits osteoblast differentiation and mineralization	[35, 66–68]
HECT	WWP2	Enhances osteogenic differentiation	[69–71]
HECT	Itch	Inhibits or enhances osteogenic differentiation; inhibits osteoclastogenesis	[84–87]
RING	APC/ C ^{CDH1}	Inhibits osteoblast differentiation and mineralization	[42]
RING	APC/ C ^{CDC20}	Enhances osteogenic differentiation	[41]
RING	TRAF4	Enhances osteogenic differentiation	[43]
RING	TRAF6	Enhances osteoclast differentiation	[44–46]
RING	TRIM21	Inhibits osteogenic differentiation	[51]
RING	TRIM33	Protects osteoblasts against oxidative stress-induced apoptosis in osteoporosis	[52, 53]
RING	TRIM38	Enhances osteogenic differentiation; inhibits osteoclastogenesis	[54]
RING	RNF40	Enhances osteogenic differentiation	[56, 57]
RING	RNF146	Enhances osteogenic differentiation; inhibits osteoclastogenesis	[58–60]
RING	RNF185	Inhibits osteoblast differentiation and mineralization	[61]
RING	Mdm2	Enhances osteogenic differentiation	[76, 77]
RING	Cbl-b and c-Cbl	Inhibits osteoblast differentiation and mineralization; enhances osteogenic differentiation	[6, 91–95]
RING	LNX2	Enhances osteoclast differentiation	[99]
RING	Arkadia	Enhances osteogenic differentiation	[105]
B-box	TRIM16	Enhances osteogenic differentiation	[49, 50]
F-box	SCF ^{Skp2}	Inhibits osteoblast differentiation and mineralization	[80]
F-box	FBL12	Inhibits osteoblast differentiation and mineralization	[96, 97]
U-box	CHIP	Inhibits osteoblast differentiation and mineralization; inhibits osteoclastogenesis	[88, 89]
RBR	Parkin	Enhances osteogenic differentiation	[102, 103]

the SMAD2/3 pathways [19]. However, TGF- β 1 promotes the ubiquitination and degradation of TGF- β 1 type I receptor by inducing SMURF1 and SMURF2, which in turn inhibits osteoblast mineralization during the late stages of osteoblast differentiation [20–22]. Moreover, TGF- β 1 degrades the C/EBP β protein by inducing SMURF1 expression at the transcriptional level, thereby reducing C/EBP β -DKK1 and inhibiting matrix mineralization during osteoblast differentiation [23].

RAS-MAPK-ERK signaling pathway also plays a dual role in bone metabolism. Crosstalk exists between the TGF- β /BMP-SMAD and RAS-MAPK signaling pathways [24]. TGF- β can upregulate the expression of SMURF1 by activating the MAPK-ERK pathway, then increase the proteasome degradation of RUNX2 and SMAD1, and inhibit osteogenic differentiation [25]. Furthermore, SMURF1 can directly interact with MEKK2 and affect the activation of the downstream JNK signal cascade [26].

Tumor necrosis factor (TNF) is a proinflammatory cytokine which is one of the main factors involved in pathological bone loss [27]. One of the mechanisms of TNF in inflammatory bone disease is the induction of the expression of the ubiquitin ligases SMURF1 and SMURF2, thus promoting the ubiquitination degradation of SMAD1/5 and RUNX2 and leading to systemic bone loss [28, 29]. The possible molecular mechanism underlying is that the presence of AP-1, RUNX2, and TNF- α activates JNK and ERK, which induces JNK binding of RUNX2 and c-Jun to the SMURF1 promoter, thus promoting SMURF1 transcription [30].

Furthermore, SMURF1 can regulate cell polarity and process formation by targeting the RhoA ubiquitination degradation [31] and negatively regulating MSC proliferation and differentiation by promoting JunB degradation [32]. Continuous PTH treatment can increase SMURF1 expression in osteoblasts, leading to RUNX2 degradation and reducing anti-apoptotic signaling in osteoblasts [33] (Figure 1).




FIGURE 1: The E3 ubiquitin ligase SMURF1 mediates the ubiquitination and degradation of key factors from BMP/TGF- β pathway, NF- κ B pathway, MAPK pathway, and other pathways, thereby regulating osteogenic differentiation. Notably, these pathways interconnected with each other and formed a complex regulatory network.

2.2. *SMURF2*. SMURF2 is an E3 ligase of the Hect family which mainly regulates TGF- β /BMP signaling through a pathway similar to but independent of SMURF1. SMURF2 preferentially targets SMAD1 for ubiquitination and degradation and has weaker affinity for SMAD2 and SMAD3 [34]. In addition, when SMURF2 was coexpressed with R-SMAD and SMAD2, SMURF2 showed the ability to down-regulate SMAD4 similarly to SMURF1 [35]. Under IFN γ induction, SMURF2 and inhibitory SMADs (such as SMAD7) form a SMAD7-SMURF2 complex, which targets TGF- β receptors for degradation and thus bone metabolism [36]. A study showed that SMURF2 mice showed severe osteoporosis with an increased number of osteoclasts. A possible mechanism is that SMURF2-mediated SMAD3 ubiquitination affects the interaction between SMAD3 and vitamin D receptors, which regulates RANKL expression [37]. AKT is one of the key cytokines in bone anabolic signaling [12], and the PI3-kinase-AKT pathway intersects with the BMP pathway. Experiments have shown that AKT enhances RUNX2 expression by inducing SMURF2 ubiquitination and degradation which enhances the stability of the RUNX2 protein [38]. SMURF2 also stimulates chondrocyte maturation during endochondral ossification. Specifically, SMURF2 induces GSK-3 β ubiquitination and proteasome degradation, leading to the upregulation of β -catenin which promotes endochondral ossification via the Wnt signaling pathway [39].

2.3. *APC/C^{CDC20}* and *APC/C^{Cdh1}*. The anaphase-promoting complex or cyclosome (APC/C) is a multisubunit ubiquitin ligase that regulates multiple cell cycle transitions. Two APC/C activators, Cdc20 and Cdh1, directly bind to APC/C, activate its ubiquitin ligase activity, and contribute to its substrate recognition and specificity [40]. APC/C also has cell cycle-independent functions. APC/C^{CDC20} promoted

the osteogenic differentiation of BMSCs by ubiquitination and degradation of p65 [41]. Conversely, the interaction between Cdh1 and SMURF1 enhances Smurf1-mediated ubiquitination of its downstream targets and inhibits osteoblast differentiation by regulating the activity of the MEKK2 pathway [42].

2.4. *TRAF4*. TNF receptor-associated factor 4 (TRAF4), a member of the TRAF family and a ubiquitin ligase in the RING family, plays an important role in the embryogenesis and development of the skeletal system. It was demonstrated that TRAF4 acts as an E3 ubiquitin ligase that positively regulates the osteogenesis of MSCs by mediating the ubiquitination of the K48 linkage of SMURF2 at the K119 locus and leading to its degradation [43].

2.5. *TRAF6*. Tumor necrosis factor receptor-associated factor 6 (TRAF6), a ubiquitin ligase in the RING family, is a key bridging molecule of the NF- κ B pathway and plays an important role in the regulation of osteoclast formation. Previous studies have shown that TRAF6-deficient mice have bone abnormalities and osteosclerosis [44]. TRAF6 is essential for RANKL signaling and osteoclast differentiation. RANKL recruits TRAF6 binding to E2 ligase Ubc13/Uev1A which promotes site-specific autoubiquitination, thus activating the IKK/NF- κ B and JNK/SAPK pathways which promote osteoclast differentiation [45, 46].

2.6. TRIM Family

2.6.1. *TRIM16*. The TRIM protein family includes about 75 proteins with E3 ligase activity and has multiple functions in proliferation, differentiation, apoptosis, carcinogenesis, and autophagy [47]. TRIM16, which belongs to the TRIM family, does not have a RING domain but has E3 ubiquitin ligase activity [48]. A study has shown that TRIM16 and

Galectin-3 coregulate the osteogenic differentiation of hBMSCs [49]. Furthermore, TRIM16 reduces CHIP, which reduces CHIP-mediated RUNX2 degradation, thus promoting osteogenic differentiation of hPDLSCs [50].

2.6.2. TRIM21. Tripartite motif containing 21 (TRIM21) is a member of the TRIM protein family with E3 ubiquitin ligase activity. TRIM21 modulated the osteogenic process of MSCs by acting as an E3 ubiquitin ligase to mediate the K48-linked ubiquitination of Akt and cause degradation [51].

2.6.3. TRIM33. Triplex protein 33 (TRIM33) is a member of the TRIM family and a RING type E3 ubiquitin ligase. TRIM33 acts as a positive regulator of osteoblast differentiation in the BMP pathway and its action is mediated by its interaction and activation with Smad1/5 [52]. In addition, TRIM33 protects osteoblasts against oxidative stress-induced apoptosis in osteoporosis by inhibiting ubiquitination and degradation of FOXO3a [53].

2.6.4. TRIM38. Triplex protein 38 (TRIM38) is a member of the TRIM family and a RING type E3 ubiquitin ligase. TRIM38 is involved in various cellular processes such as proliferation, differentiation, apoptosis, and antiviral defense. TRIM38 regulates the NF- κ B pathway involved in osteoclast and osteoblast differentiation through ubiquitination and degradation of TGF- β 1 Activated Kinase 1 (MAP3K7) Binding Protein 2 (TAB2) protein. Overexpression of TRIM38 in osteoclast precursor cells attenuates RANKL-induced NF- κ B activation and osteoblast proliferation and differentiation. Ectopic expression of TRIM38 in osteoblast precursors negatively regulates NF- κ B activation and promotes BMP2-induced I κ B α phosphorylation and degradation for osteoblast differentiation [54].

2.7. RNF40. RNF40, a RING family of E3 ubiquitin ligases, monoubiquitinates histone H2A at K119 or H2B at K120, is known to function in transcriptional elongation, DNA double-strand break (DSB) repair processes, maintenance of chromatin differentiation, and exerting tumor suppressor activity [55]. A recent study has found that RNF40-driven H2B monoubiquitination is important for bone integrity in osteoblasts. RNF40 expression is essential for the early stages of lineage specification but is dispensable in mature osteoblasts [56, 57].

2.8. RNF146. RNF146 is a RING domain E3 ubiquitin ligase. Mice lacking RNF146 develop a syndrome similar to craniosynostosis dysplasia (CCD) [58]. AXIN is a key node in the Wnt pathway, and RNF146 controls the Wnt/ β -linked protein pathway through ubiquitination of its substrate AXIN to inhibit osteolysis [59]. 3BP2 is the bridging protein required for the activation of SRC tyrosine kinases and coordinates the attenuation of β -linked proteins, which are necessary for osteoclast development. RNF146 also affects bone remodeling via 3BP2 ubiquitination. Furthermore, by regulating the WNT3a-FGF18-TAZ axis, RNF146 can promote osteoblast differentiation and proliferation [60]. Overall, RNF146 regulates the 3BP2/SRC and Wnt/ β -catenin path-

ways on bone metabolism by ubiquitination of 3BP2 and AXIN1.

2.9. RNF185. RNF185, a RING type E3 ubiquitin ligase, inhibits osteogenic differentiation of mouse cranial-derived MC3T3-E1 cells. The mechanism is the interaction between RNF185 and Dvl2, a key mediator of the Wnt signaling pathway. RNF185 inhibits Wnt signaling and negatively regulates osteogenesis by promoting ubiquitin and degradation of Dvl2 [61].

2.10. NEDD4 Family

2.10.1. NEDD4-1. NEDD4/NEDD4-1, an E3 ubiquitin ligase in the NEDD4 family, is essential for osteoblast differentiation and proliferation. Lack of Nedd4 in preosteoblasts results in reduced cell proliferation and altered osteogenic differentiation. Nedd4 promotes the expansion of osteoblast progenitor cell pools which plays an important role in craniofacial development [62]. NEDD4 promotes bone formation primarily by enhancing TGF- β 1 signaling. NEDD4 promotes osteoblast proliferation by degrading PTEN and TGF- β 1-activated pSMAD1, upregulating pSMAD2, and promoting TGF- β 1 gene expression by upregulating PERK1/2 [63, 64].

2.10.2. NEDD4-2. NEDD4-2/NEDD4L is an E3 ubiquitin ligase in the NEDD4 family. NEDD4-2/NEDD4L is similar to SMURF1 and SMURF2. Under SMAD7 participation, NEDD4-2 mediates its degradation by interacting with T β R-I. In addition, NEDD4-2 interacts with SMAD2 and induces its ubiquitination and degradation. In general, NEDD4-2 negatively regulates the TGF- β and BMP signaling pathways [65].

2.11. WWP Family

2.11.1. WWP1. WWP1 is a member of the SMURF-like C2-WW-HECT (WW is Trp-Trp and HECT is homologous to the E6-accessory protein) type E3 ubiquitin ligases. WWP1 inhibits osteogenesis by promoting SMAD4 in osteoblasts and RUNX2 ubiquitination [35, 66]. In patients with chronic inflammatory diseases, elevated TNF inhibits bone formation through a variety of mechanisms. Junb protein is a key transcription factor that modulates MSCs to differentiate into osteoblasts. Under TNF-mediated mechanisms, WWP1 targets Junb protein proteasome degradation which inhibits bone formation [67]. In addition, WWP1 negatively regulates bone mass by inhibiting MSC migration and osteoblast differentiation. It was also found that WWP1 expression is lower in young MSCs and increases with aging [68].

2.11.2. WWP2. WWP2 is a member of the SMURF-like C2-WW-HECT type E3 ubiquitin ligases, which promotes Sox6 expression through monoubiquitination of Goosecoid under the transcriptional regulation of Sox9 and then promotes craniofacial development [69]. Besides, both WWP2 and Med25 could enhance Sox9 transcriptional activity [70]. Moreover, WWP2 promotes osteogenesis by enhancing RUNX2 through nonproteolytic monoubiquitination [71].

2.12. MDM2. MDM2 is an important negative regulator of p53 and an E3 enzyme, which promotes p53 degradation by p53 ubiquitination. P53 is an important tumor suppressor gene in the apoptosis pathway. P53, as a transcription factor, regulates cell cycle arrest, DNA repair, and apoptosis [72]. MDM2 suppresses the action of p53 on the MDM2 gene response element, thus forming a p53-MDM2 regulatory feedback loop. Therefore, in normal cells, p53 is continuously degraded through MDM2-mediated ubiquitination, resulting in a sustained low expression level of p53 [73]. Studies have shown that p53 inhibits osteoblast differentiation and osteoma formation by inhibiting the expression of RUNX2 or Osterix without affecting osteoclast differentiation [74, 75]. MDM2 negatively regulates p53 in favor of RUNX2 activation and is one of the necessary conditions for osteoblast differentiation and appropriate bone formation [76]. Dlx3 is a transcription factor that plays an important role in odontoblast differentiation. MDM2-ubiquitinated Dlx3 upregulates Dspp expression, and MDM2 ubiquitinates P53, which degrades it, reducing the inhibitory effect of mDPCs on odontoblast-like differentiation [77].

2.13. SCF^{SKP2}. SKP2 is a SCF family protein, and its complex with SKP1 and CUL1 (SCF^{SKP2}) is an E3 ubiquitin ligase [78]. This plays an important role in regulating the cell cycle [79]. SKP2 targets RUNX2 for ubiquitin-mediated degradation and thus negatively regulates osteogenesis. Moreover, RUNX2 and SKP2 expression levels in vivo are negatively related [80]. Therefore, SKP2 may be a therapeutic target for osteoporosis.

2.14. ITCH. ITCH is a HECT family E3 ligase containing the WW domain. ITCH E3 ubiquitin ligase deficiency in humans and mice leads to syndromic multisystem autoimmune disease [81]. The molecular mechanism of ITCH deficiency leading to autoimmune disease and multiorgan inflammation is related to its negative regulation of JNK and NF- κ B signaling pathways [82, 83]. Therefore, the investigators found that Itch negatively regulates osteoblast differentiation from bone marrow mesenchymal stem cells through proteasome degradation of JunB protein [84]. Furthermore, Itch binds to the N-terminal part of NICD through its WW structural domain and inhibits the Notch pathway by promoting Notch ubiquitination through its HECT ubiquitin ligase structural domain [85]. Itch deficiency leads to increased expression of the Notch signal pathway and reduced differentiation of MSCs into osteoblasts, therefore resulting in osteopenic bone phenotype [86]. A study also noted an increase in osteoclasts in the bone marrow of ITCH^{-/-} mice. One of the mechanisms is that ITCH promotes the deubiquitination of TRAF6 by recruiting CYLD to TRAF6 signal transduction complexes. TRAF6 plays an important role in RANKL signal transduction in osteoclasts and osteoclast precursors (OCP). Thus, deubiquitinated TRAF6 negatively regulates osteoclast formation via the RANKL signaling pathway [87].

2.15. CHIP. The carboxyl terminus of Hsp70 interacting protein (CHIP or STUB1) is an E3 ligase that regulates the

stability of several proteins involved in different cellular functions. Deletion of the CHIP gene leads to a reduced bone mineral phenotype and increased osteoclast formation. CHIP interacts with TRAF6 to promote TRAF6 ubiquitination and proteasomal degradation, thereby inhibiting TRAF6-mediated NF- κ B signaling, and plays an important role in osteoclastogenesis and bone reconstruction [88]. In addition to regulating TRAF6, CHIP inhibits TNF α -induced NF- κ B signaling by promoting the degradation of TRAF2 and TRAF5 [89].

2.16. Cbl-b and c-Cbl. The Cbl (Casitas b lineage lymphoma) proteins are an evolutionarily conserved protein family that includes three different gene products (Cbl or c-Cbl; Cbl-b; and Cbl-c, Cbl-3, or Cbl-SL). Cbl-b and c-Cbl proteins are members of the mammalian CBL (Casitas B lineage lymphoma) family and are also Ring E3 ubiquitin ligases which regulate bone metabolism [90]. The effects of Cbl-b and c-Cbl on bone metabolism have been extensively studied, with the literature suggesting that Cbl proteins control osteoblast proliferation, differentiation, and survival through ubiquitination affecting the RTK-PI3K-AKT axis and other c-Cbl target proteins [6, 91, 92]. In addition, Cbl-b and c-Cbl have some less noticeable regulatory effects on bone metabolism. Osterix (also known as Sp7) is an osteogenic-specific cellular regulator which acts downstream of RUNX2 [93]. It was found that Cbl-b/C-cbl reduced the function of Osterix by degrading Osterix with ubiquitin, which inhibited bmp2-mediated osteogenic differentiation [94]. Cbl-b has been shown to be significantly increased in osteoblasts of denervated mice which inhibits IGF-I-regulated osteogenic differentiation by increasing IRS-1 ubiquitination and degradation during denervation [95].

2.17. FBL12. FBL12 is an F-box protein induced by TGF- β 1. p57^{KIP2} is a cyclin-dependent kinase (CDK) inhibitor (CKI) that plays an important role in cell proliferation and differentiation and affects bone development [96]. Under the stimulation of TGF- β 1, FBL12 and SCF form the SCF FBL12 complex, which directly ubiquitinates p57^{KIP2} and leads to its degradation, thereby inhibiting osteoblast differentiation [97].

2.18. LNX2. Notch signaling regulates proliferation, differentiation, and apoptosis in a cell-cell contact-dependent manner. It plays a crucial role in regulating the proliferation and differentiation of osteoblasts and osteoclasts in skeletal development and homeostasis in vivo [98]. LNX2 is a RING-type E3 ubiquitin ligase, which promotes the activation of ERK and AKT induced by M-CSF and the activation of NF- κ B and JNK pathways stimulated by RANKL, which in turn promote osteoclast differentiation. Numb protein is an inhibitor of the Notch pathway and LNX2 binding to Numb mediates its ubiquitinated degradation and inhibits Numb-mediated inhibition of osteoblast differentiation by downregulation of the Notch pathway [99].

2.19. Parkin. Parkin (Park2) is a RING-between-RING (RBR) E3 ligase [100]. Parkin can be recruited to mitochondria and mediates mitochondrial autophagy, which is related

to the pathogenesis of Parkinson's disease [101]. It reduces ROS levels and inhibits apoptosis in osteoarthritic chondrocytes by promoting mitophagy to eliminate damaged/depolarized mitochondria [102]. What is more, Parkin promotes osteoblast differentiation of BMSCs by enhancing autophagy and β -catenin signaling pathway [103]. NIPA2 is a selective Mg^{2+} transporter and helps maintain Mg^{2+} influx. NIPA2 was found to be associated with the development of type 2 diabetic osteoporosis via the mitophagy pathway. The possible mechanism underlying this is that PINK1/Parkin-mediated mitochondrial autophagy in osteoblasts is regulated by NIPA2, which is regulated by the PGC-1 α /FoxO3a/MMP pathway [104].

2.20. Arkadia. Arkadia, a RING-type E3 ubiquitin ligase, is a positive regulator of the TGF- β family of SMAD-dependent signaling pathways. Arkadia promotes BMP-induced osteoblast differentiation by downregulating the BMP-specific negative regulators SMAD6, SMAD7, and c-Ski/SnoN to positively regulate BMP signaling [105].

3. UPS Inhibitors and Drugs Regulate Skeletal Cell Fate and Pathology

The most commonly used UPS inhibitors in clinical practice are proteasome inhibitors. In 2003, bortezomib (BTZ) became the first proteasome inhibitor approved by the U.S. Food and Drug Administration (FDA). BTZ has been shown to positively affect bone metabolism in MM and promote bone anabolism [106]. It directly inhibits osteoclastogenesis and promotes osteoblastogenesis [107]. Specifically, BTZ can upregulate BMP-2 expression and prevent the proteolytic degradation of the osteoblast transcription factor RUNX2/Cbfa1 to regulate osteoblast differentiation [33, 108]. BTZ inhibits osteoclast differentiation by inhibiting DKK1, RANKL, and NF- κ B pathway activity [109, 110]. Experiments have shown that BTZ decreases skeletal complications of MM and prevents mechanical unloading-induced bone loss and ovariectomy-induced osteoporosis in mice [111–113].

In addition to specially developed UPS inhibitors, some commonly used drugs have also been found to be involved in bone metabolism through the UPS system, including thalidomide, lansoprazole, carnosic acid, melatonin, clomipramine, zoledronic acid, and Vitisin A. The immunomodulatory drug (IMiD) thalidomide was originally considered a teratogenic agent but is now used to treat a variety of clinical indications, including MM. It has been found that the direct target of thalidomide is the Cereblon (CRBN), a component of the cullin-4 RING E3 ligase complex. Thalidomide inhibits the ubiquitination of CRBN, leading to increased cullin-4 RING E3 ligase-mediated degradation of target proteins [114]. Recent studies indicate thalidomide has inhibitory effects on glucocorticoid-induced osteoporosis and ovariectomy-induced osteoporosis in mice, but excessive doses of thalidomide can exacerbate osteoporosis [115, 116]. Lansoprazole, which is one of the most commonly prescribed drugs for the treatment of acid-related diseases, induces TRAF6 polyubiquitination, which then activates the noncanonical TAK1-p38 MAPK pathway and facilitates Runx2-mediated osteoblastogenesis [117]. Car-

nolic acid (CA) is a phenolic acid compound first found in *Salvia officinalis* L., which possesses antioxidative and antimicrobial properties [118]. CA dually targets SREBP2 and ERR α , thus inhibiting the RANKL-induced osteoclast formation and improving OVX-induced bone loss [119]. Melatonin is a signal molecule that modulates the biological circadian rhythms of vertebrates. Melatonin treatment was found to downregulate TNF α -induced SMURF1 expression and then decrease SMURF1-mediated ubiquitination and degradation of SMAD1 protein, leading to steady bone morphogenetic protein-SMAD1 signaling activity and restoration of TNF α -impaired osteogenesis [120]. Recent studies have shown that clomipramine (CLP) induces bone loss and osteoporosis by acting on Itch to promote osteoclastogenesis. On the contrary, bisphosphonates, such as zoledronic acid (ZA) and prevent bone loss from CLP treatment [121]. One such mechanism is zoledronic acid- (ZA-) induced osteoclast cell ferroptosis by triggering FBXO9-mediated p53 ubiquitination and degradation [122]. A study found that oral administration of a drug containing (+)-Vitisin A significantly improves bone loss in ovariectomized mice. (+)-Vitisin A inhibits RANKL-induced ubiquitination of TRAF6 and formation of the TRAF6-TAK1 complex which inhibits activation of the IKK/NF- κ B/c-Fos/NFATc1 signaling pathway to inhibit osteoclast differentiation [123].

There are also a considerable number of E3 ligase drugs in preclinical or clinical trials [124, 125]. The issue is that most of these inhibitors are more effective in cell culture studies and less effective in animal models and clinical trials. Therefore, further research and technological advances will be required in the future [125].

4. Noncoding RNAs Regulate Skeletal Cell Fate through the UPS System

Noncoding RNAs (ncRNAs) include intronic RNAs, microRNAs (miRNAs), long noncoding RNAs (lncRNA), circular RNAs (circRNA), and extracellular RNAs [126]. The ability of ncRNAs to control gene expression makes them viable targets for drug development. To date, several ncRNAs were found to act on E3 ubiquitin ligases to regulate bone metabolism. The lncRNA RP11-527N22.2, named osteogenic differentiation inhibitory lncRNA 1 (ODIR1), acts as a key negative regulator during the osteogenic differentiation of hUC-MSCs through the FBXO25/H2BK120ub/H3K4me3/OSX axis [127]. miR-142-5p promoted osteoblast activity and matrix mineralization by targeting the gene encoding WW-domain-containing E3 ubiquitin protein ligase 1 [128]. miR-25 secreted by BMSC-Exo regulates the ubiquitination degradation of Runx2 by SMURF1 to promote fracture healing in mice [129]. Mesenchymal stem cell-derived exosomal miR-19b represses the expression of WWP1 or Smurf2 and elevates KLF5 expression through the Wnt/ β -catenin signaling pathway, thereby facilitating fracture healing [130]. BMSC-derived exosomal miR-101 augments osteogenic differentiation in MSCs by inhibiting FBXW7 to regulate the HIF1 α /FOXP3 axis [131]. Silencing DCAF1 by miR-3175 activated Nrf2 signaling to inhibit dexamethasone-induced oxidative injury and apoptosis in human osteoblasts [132].

miR-764-5p positively regulates osteoblast differentiation from osteoblast progenitor cells by inhibiting CHIP protein translation [133]. In addition, biomaterials have also been used as drug delivery platforms to deliver ncRNA. In this research, regenerative siRNA against WW domain-containing E3 ubiquitin protein ligase 1 (Wwp1) complexed with hybrid nanoparticle (NP) were entrapped within poly (ethylene glycol) (PEG)-based hydrogels and implanted at sites of murine middiaphyseal femur fractures. Results showed that fractures treated with siRNA/NP hydrogels exhibited accelerated bone formation and significantly increased biomechanical strength [134].

5. Conclusions

Recognition and understanding of the role of the ubiquitin-proteasome system in osteogenic regulation have gained significance in the past decades. Its discovery has helped us understand the nature of biochemical processes behind major developmental and homeostatic events. Numerous ubiquitin enzymes have been discovered so far, with E3 ubiquitin ligases being the most important and diverse. In this review, we discuss and present the role of E3 ubiquitin ligases in bone metabolism, drawing from historical studies on E3 ubiquitin ligases in bone metabolism, as well as recent findings. They regulate bone metabolism through several key factors and pathways that act on osteogenesis and osteoclast.

Designing therapies that target each component of the UPS in order to treat pathology holds great promise for clinical practice. Some proteasome inhibitors are already in clinical use and have been shown to be effective in the treatment of multiple myeloma. Some of these drugs, such as bortezomib, were found to prevent osteoporosis in mice. The main pharmacological effects of some clinical drugs such as thalidomide, lansoprazole, carnosic acid, melatonin, clomipramine, zoledronic acid, and Vitisin A are not related to the UPS system. However, several recent studies have found that these clinical drugs could affect different E3 ubiquitin ligases, which in turn regulate different bone metabolic pathways. Noncoding RNAs, such as miRNA, lncRNA, and siRNA, have also been used to regulate bone metabolism by targeting the UPS system. However, the application of noncoding RNAs is challenged by their poor stability, poor pharmacokinetics, and potential off-target effect. The use of corresponding biomaterials will greatly improve the therapeutic efficacy of noncoding RNA. But the research in this area is relatively basic, and there is still room for further improvement. Moreover, there are a considerable number of E3 ligase drugs in preclinical or clinical trials. Further research and technological advances such as PROTAC (Proteolysis targeting chimeras) may take the research to a new level [135]. With the further discovery of the mechanisms of the E3 ubiquitin ligases related to bone metabolism, more drugs targeting E3 ligases will be designed for the treatment of skeletal disorders.

Conflicts of Interest

All authors declare no conflicts of interest.

Authors' Contributions

Ruiyin Zeng, Yuan Xiong and Ze Lin contributed equally to this work.

Acknowledgments

This work was supported by the National Natural Science Foundation of China (No. 82002313 and No. 82072444), National Key Research and Development Program of China (Nos. 2018YFC2001502 and 2018YFB1105705), Department of Science and Technology of Hubei Province (No. 2020BCB004), and Hubei Province Key Laboratory of Oral and Maxillofacial Development and Regeneration (No. 2020kqhm002 and No. 2020kqhm008).

References

- [1] Y. C. Guo, S. W. Zhang, and Q. Yuan, "Deubiquitinating enzymes and bone remodeling," *Stem Cells International*, vol. 2018, Article ID 3712083, 9 pages, 2018.
- [2] A. Suzuki, M. Minamide, C. Iwaya, K. Ogata, and J. Iwata, "Role of metabolism in bone development and homeostasis," *International Journal of Molecular Sciences*, vol. 21, no. 23, p. 8992, 2020.
- [3] J. R. Edwards and G. R. Mundy, "Advances in osteoclast biology: old findings and new insights from mouse models," *Nature Reviews Rheumatology*, vol. 7, no. 4, pp. 235–243, 2011.
- [4] D. S. Amarasekara, S. Kim, and J. Rho, "Regulation of osteoblast differentiation by cytokine Networks," *International Journal of Molecular Sciences*, vol. 22, no. 6, p. 2851, 2021.
- [5] J. Kular, J. Tickner, S. M. Chim, and J. Xu, "An overview of the regulation of bone remodelling at the cellular level," *Clinical Biochemistry*, vol. 45, no. 12, pp. 863–873, 2012.
- [6] N. Sévère, F. X. Dieudonné, and P. J. Marie, "E3 ubiquitin ligase-mediated regulation of bone formation and tumorigenesis," *Cell Death & Disease*, vol. 4, no. 1, article e463, 2013.
- [7] D. Wang, L. Ma, B. Wang, J. Liu, and W. Wei, "E3 ubiquitin ligases in cancer and implications for therapies," *Cancer Metastasis Reviews*, vol. 36, no. 4, pp. 683–702, 2017.
- [8] X. Li, E. Elmira, S. Rohondia, J. Wang, J. Liu, and Q. P. Dou, "A patent review of the ubiquitin ligase system: 2015–2018," *Expert Opinion on Therapeutic Patents*, vol. 28, no. 12, pp. 919–937, 2018.
- [9] M. Wu, G. Chen, and Y. P. Li, "TGF- β and BMP signaling in osteoblast, skeletal development, and bone formation, homeostasis and disease," *Bone Research*, vol. 4, no. 1, article 16009, 2016.
- [10] S. J. Rodda and A. P. McMahon, "Distinct roles for hedgehog and canonical Wnt signaling in specification, differentiation and maintenance of osteoblast progenitors," *Development*, vol. 133, no. 16, pp. 3231–3244, 2006.
- [11] N. Van Gestel and G. Carmeliet, "Metabolic regulation of skeletal cell fate and function in physiology and disease," *Nature Metabolism*, vol. 3, no. 1, pp. 11–20, 2021.
- [12] N. Kawamura, F. Kugimiya, Y. Oshima et al., "Akt1 in osteoblasts and osteoclasts controls bone Remodeling," *PLoS One*, vol. 2, no. 10, article e1058, 2007.

- [13] A. Salhotra, H. N. Shah, B. Levi, and M. T. Longaker, "Mechanisms of bone development and repair," *Nature Reviews. Molecular Cell Biology*, vol. 21, no. 11, pp. 696–711, 2020.
- [14] P. Xu, X. Lin, and X. H. Feng, "Posttranslational regulation of Smads," *Cold Spring Harbor Perspectives in Biology*, vol. 8, no. 12, 2016.
- [15] L. Fu, C. P. Cui, X. Zhang, and L. Zhang, "The functions and regulation of Smurfs in cancers," *Seminars in Cancer Biology*, vol. 67, Part 2, pp. 102–116, 2020.
- [16] G. Murakami, T. Watabe, K. Takaoka, K. Miyazono, and T. Imamura, "Cooperative inhibition of bone morphogenetic protein signaling by Smurf1 and inhibitory Smads," *Molecular Biology of the Cell*, vol. 14, no. 7, pp. 2809–2817, 2003.
- [17] R. Shen, M. Chen, Y. J. Wang et al., "Smad6 interacts with Runx2 and mediates Smad ubiquitin regulatory factor 1-induced Runx2 degradation," *The Journal of Biological Chemistry*, vol. 281, no. 6, pp. 3569–3576, 2006.
- [18] F. Yang, N. Xu, D. Li et al., "A feedback loop between RUNX2 and the E3 ligase SMURF1 in regulation of differentiation of human dental pulp stem cells," *Journal of Endodontia*, vol. 40, no. 10, pp. 1579–1586, 2014.
- [19] G. Chen, C. Deng, and Y. P. Li, "TGF- β and BMP signaling in osteoblast differentiation and bone formation," *International Journal of Biological Sciences*, vol. 8, no. 2, pp. 272–288, 2012.
- [20] M. Datto and X. F. Wang, "Ubiquitin-Mediated Degradation: A Mechanism for Fine-Tuning TGF- β Signaling," *Cell*, vol. 121, no. 1, pp. 2–4, 2005.
- [21] S. Maeda, M. Hayashi, S. Komiya, T. Imamura, and K. Miyazono, "Endogenous TGF- β signaling suppresses maturation of osteoblastic mesenchymal cells," *The EMBO Journal*, vol. 23, no. 3, pp. 552–563, 2004.
- [22] T. Ebisawa, M. Fukuchi, G. Murakami et al., "Smurf1 Interacts with Transforming Growth Factor- β Type I Receptor through Smad7 and Induces Receptor Degradation," *The Journal of Biological Chemistry*, vol. 276, no. 16, pp. 12477–12480, 2001.
- [23] B. Nam, H. Park, Y. L. Lee et al., "TGF β 1 suppressed matrix mineralization of osteoblasts differentiation by regulating SMURF1-C/EBP β -DKK1 axis," *International Journal of Molecular Sciences*, vol. 21, no. 24, p. 9771, 2020.
- [24] A. Schindeler and D. G. Little, "Ras-MAPK signaling in osteogenic differentiation: friend or foe?," *Journal of Bone and Mineral Research*, vol. 21, no. 9, pp. 1331–1338, 2006.
- [25] X. Sun, Z. Xie, Y. Ma et al., "TGF- β inhibits osteogenesis by upregulating the expression of ubiquitin ligase SMURF1 via MAPK-ERK signaling," *Journal of Cellular Physiology*, vol. 233, no. 1, pp. 596–606, 2018.
- [26] M. Yamashita, S. X. Ying, G. M. Zhang et al., "Ubiquitin Ligase Smurf1 Controls Osteoblast Activity and Bone Homeostasis by Targeting MEKK2 for Degradation," *Cell*, vol. 121, no. 1, pp. 101–113, 2005.
- [27] Q. Mo, W. Zhang, A. Zhu, L. J. Backman, and J. Chen, "Regulation of osteogenic differentiation by the pro-inflammatory cytokines IL-1 β and TNF- α : current conclusions and controversies," *Human Cell*, vol. 35, no. 4, pp. 957–971, 2022.
- [28] R. Guo, M. Yamashita, Q. Zhang et al., "Ubiquitin Ligase Smurf1 Mediates Tumor Necrosis Factor-induced Systemic Bone Loss by Promoting Proteasomal Degradation of Bone Morphogenetic Signaling Proteins," *The Journal of Biological Chemistry*, vol. 283, no. 34, pp. 23084–23092, 2008.
- [29] H. Kaneki, R. Guo, D. Chen et al., "Tumor necrosis factor promotes Runx2 degradation through up-regulation of Smurf1 and Smurf2 in osteoblasts," *The Journal of Biological Chemistry*, vol. 281, no. 7, pp. 4326–4333, 2006.
- [30] H. L. Lee, T. Yi, K. Baek et al., "Tumor necrosis factor- α enhances the transcription of Smad ubiquitination regulatory factor 1 in an activating protein-1- and Runx2-dependent manner," *Journal of Cellular Physiology*, vol. 228, no. 5, pp. 1076–1086, 2013.
- [31] H. R. Wang, Y. Zhang, B. Ozdamar et al., "Regulation of cell polarity and protrusion formation by targeting RhoA for Degradation," *Science*, vol. 302, no. 5651, pp. 1775–1779, 2003.
- [32] L. Zhao, J. Huang, R. Guo, Y. Wang, D. Chen, and L. Xing, "Smurf1 inhibits mesenchymal stem cell proliferation and differentiation into osteoblasts through JunB degradation," *Journal of Bone and Mineral Research*, vol. 25, no. 6, pp. 1246–1256, 2010.
- [33] T. Bellido, A. A. Ali, L. I. Plotkin et al., "Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism," *The Journal of Biological Chemistry*, vol. 278, no. 50, pp. 50259–50272, 2003.
- [34] Y. Bai and Y. Ying, "The post-translational modifications of Smurf2 in TGF- β Signaling," *Frontiers in Molecular Biosciences*, vol. 7, p. 128, 2020.
- [35] A. Morén, T. Imamura, K. Miyazono, C. H. Heldin, and A. Moustakas, "Degradation of the tumor suppressor Smad4 by WW and HECT domain ubiquitin ligases," *The Journal of Biological Chemistry*, vol. 280, 23 pages, 2005.
- [36] P. Kavsak, R. K. Rasmussen, C. G. Causing et al., "Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF β receptor for degradation," *Molecular Cell*, vol. 6, no. 6, pp. 1365–1375, 2000.
- [37] Z. Xu, M. B. Greenblatt, G. Yan et al., "SMURF2 regulates bone homeostasis by disrupting SMAD3 interaction with vitamin D receptor in osteoblasts," *Nature Communications*, vol. 8, no. 1, p. 14570, 2017.
- [38] Y. H. Choi, Y. J. Kim, H. M. Jeong, Y. H. Jin, C. Y. Yeo, and K. Y. Lee, "Akt enhances Runx2 protein stability by regulating Smurf2 function during osteoblast differentiation," *The FEBS Journal*, vol. 281, no. 16, pp. 3656–3666, 2014.
- [39] Q. Wu, D. Chen, M. J. Zuscik, R. J. O'keefe, and R. N. Rosier, "Overexpression of Smurf2 stimulates endochondral ossification through upregulation of beta-catenin," *Journal of Bone and Mineral Research*, vol. 23, no. 4, pp. 552–563, 2008.
- [40] S. Kim and H. Yu, "Mutual regulation between the spindle checkpoint and APC/C," *Seminars in Cell & Developmental Biology*, vol. 22, no. 6, pp. 551–558, 2011.
- [41] Y. Du, M. Zhang, X. Liu et al., "CDC20 promotes bone formation via APC/C dependent ubiquitination and degradation of p65," *EMBO Reports*, vol. 22, no. 9, article e52576, 2021.
- [42] L. Wan, W. Zou, D. Gao et al., "Cdh1 regulates osteoblast function through an APC/C-independent modulation of Smurf1," *Molecular Cell*, vol. 44, no. 5, pp. 721–733, 2011.
- [43] J. Li, P. Wang, Z. Xie et al., "TRAF4 positively regulates the osteogenic differentiation of mesenchymal stem cells by acting as an E3 ubiquitin ligase to degrade Smurf2," *Cell Death and Differentiation*, vol. 26, no. 12, pp. 2652–2666, 2019.

- [44] B. Zhang, L. L. Yang, S. Q. Ding et al., “Anti-osteoporotic activity of an edible traditional Chinese medicine *Cistanche deserticola* on bone metabolism of ovariectomized rats through RANKL/RANK/TRAF6-mediated signaling pathways,” *Frontiers in Pharmacology*, vol. 10, p. 1412, 2019.
- [45] B. Lamothe, A. Besse, A. D. Campos, W. K. Webster, H. Wu, and B. G. Darnay, “Site-specific Lys-63-linked tumor necrosis factor receptor-associated factor 6 auto-ubiquitination is a critical determinant of $\text{I}\kappa\text{B}$ kinase activation,” *The Journal of Biological Chemistry*, vol. 282, no. 6, pp. 4102–4112, 2007.
- [46] B. Lamothe, W. K. Webster, A. Gopinathan, A. Besse, A. D. Campos, and B. G. Darnay, “TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation,” *Biochemical and Biophysical Research Communications*, vol. 359, no. 4, pp. 1044–1049, 2007.
- [47] S. Hatakeyama, “TRIM family proteins: roles in autophagy, immunity, and carcinogenesis,” *Trends in Biochemical Sciences*, vol. 42, no. 4, pp. 297–311, 2017.
- [48] J. L. Bell, A. Malyukova, J. K. Holien et al., “TRIM16 acts as an E3 ubiquitin ligase and can heterodimerize with other TRIM family members,” *PLoS One*, vol. 7, no. 5, article e37470, 2012.
- [49] W. T. Chen, F. Zhang, X. Q. Zhao, B. Yu, and B. W. Wang, “Galectin-3 and TRIM16 coregulate osteogenic differentiation of human bone marrow-derived mesenchymal stem cells at least partly via enhancing autophagy,” *Bone*, vol. 131, article 115059, 2020.
- [50] Y. Zhao, Q. Zhai, H. Liu, X. Xi, S. Chen, and D. Liu, “TRIM16 promotes osteogenic differentiation of human periodontal ligament stem cells by modulating CHIP-mediated degradation of RUNX2,” *Frontiers in Cell and Development Biology*, vol. 8, article 625105, 2021.
- [51] J. Xian, D. Liang, C. Zhao, Y. Chen, and Q. Zhu, “TRIM21 inhibits the osteogenic differentiation of mesenchymal stem cells by facilitating K48 ubiquitination-mediated degradation of Akt,” *Experimental Cell Research*, vol. 412, no. 2, article 113034, 2022.
- [52] J. Guo, W. Qin, Q. Xing et al., “TRIM33 is essential for osteoblast proliferation and differentiation via BMP pathway,” *Journal of Cellular Physiology*, vol. 232, no. 11, pp. 3158–3169, 2017.
- [53] D. B. Zou, Z. Mou, W. Wu, and H. Liu, “TRIM33 protects osteoblasts from oxidative stress-induced apoptosis in osteoporosis by inhibiting FOXO3a ubiquitylation and degradation,” *Aging Cell*, vol. 20, no. 7, article e13367, 2021.
- [54] K. Kim, J. H. Kim, I. Kim, S. Seong, and N. Kim, “TRIM38 regulates NF- κB activation through TAB2 degradation in osteoclast and osteoblast differentiation,” *Bone*, vol. 113, pp. 17–28, 2018.
- [55] G. Sethi, M. K. Shanmugam, F. Arfuso, and A. P. Kumar, “Role of RNF20 in cancer development and progression - a comprehensive review,” *Bioscience Reports*, vol. 38, no. 4, 2018.
- [56] O. Karpiuk, Z. Najafova, F. Kramer et al., “The histone H2B monoubiquitination regulatory pathway is required for differentiation of multipotent stem cells,” *Molecular Cell*, vol. 46, no. 5, pp. 705–713, 2012.
- [57] Z. Najafova, P. Liu, F. Wegwitz et al., “RNF40 exerts stage-dependent functions in differentiating osteoblasts and is essential for bone cell crosstalk,” *Cell Death and Differentiation*, vol. 28, no. 2, pp. 700–714, 2021.
- [58] Y. Matsumoto, J. La Rose, M. Lim et al., “Ubiquitin ligase RNF146 coordinates bone dynamics and energy metabolism,” *The Journal of Clinical Investigation*, vol. 127, no. 7, pp. 2612–2625, 2017.
- [59] Y. Zhang, S. Liu, C. Mickanin et al., “RNF146 is a poly(ADP-ribose)-directed E3 ligase that regulates axin degradation and Wnt signalling,” *Nature Cell Biology*, vol. 13, no. 5, pp. 623–629, 2011.
- [60] Y. Matsumoto, J. Larose, O. A. Kent et al., “RANKL coordinates multiple osteoclastogenic pathways by regulating expression of ubiquitin ligase RNF146,” *The Journal of Clinical Investigation*, vol. 127, no. 4, pp. 1303–1315, 2017.
- [61] Y. Zhou, H. Shang, C. Zhang et al., “The E3 ligase RNF185 negatively regulates osteogenic differentiation by targeting Dvl2 for degradation,” *Biochemical and Biophysical Research Communications*, vol. 447, no. 3, pp. 431–436, 2014.
- [62] S. Wiszniak, N. Harvey, and Q. Schwarz, “Cell autonomous roles of Nedd4 in craniofacial bone formation,” *Developmental Biology*, vol. 410, no. 1, pp. 98–107, 2016.
- [63] S. A. Jeon, J. H. Lee, D. W. Kim, and J. Y. Cho, “E3-ubiquitin ligase NEDD4 enhances bone formation by removing TGF β 1-induced pSMAD1 in immature osteoblast,” *Bone*, vol. 116, pp. 248–258, 2018.
- [64] B. G. Kim, J. H. Lee, J. Yasuda, H. M. Ryoo, and J. Y. Cho, “Phospho-Smad1 modulation by nedd4 E3 ligase in BMP/TGF- β signaling,” *Journal of Bone and Mineral Research*, vol. 26, no. 7, pp. 1411–1424, 2011.
- [65] G. Kuratomi, A. Komuro, K. Goto et al., “NEDD4-2 (neural precursor cell expressed, developmentally down-regulated 4-2) negatively regulates TGF- β (transforming growth factor- β) signalling by inducing ubiquitin-mediated degradation of Smad2 and TGF- β type I receptor,” *The Biochemical Journal*, vol. 386, no. 3, pp. 461–470, 2005.
- [66] D. C. Jones, M. N. Wein, M. Oukka, J. G. Hofstaetter, M. J. Glimcher, and L. H. Glimcher, “Regulation of adult bone mass by the zinc finger adapter protein Schnurri-3,” *Science*, vol. 312, no. 5777, pp. 1223–1227, 2006.
- [67] L. Zhao, J. Huang, H. Zhang et al., “Tumor necrosis factor inhibits mesenchymal stem cell differentiation into osteoblasts via the ubiquitin E3 ligase Wwp1,” *Stem Cells*, vol. 29, 10 pages, 2011.
- [68] L. Shu, H. Zhang, B. F. Boyce, and L. Xing, “Ubiquitin E3 ligase Wwp1 negatively regulates osteoblast function by inhibiting osteoblast differentiation and migration,” *Journal of Bone and Mineral Research*, vol. 28, no. 9, pp. 1925–1935, 2013.
- [69] W. Zou, X. Chen, J. H. Shim et al., “The E3 ubiquitin ligase Wwp2 regulates craniofacial development through monoubiquitylation of Goosecoid,” *Nature Cell Biology*, vol. 13, no. 1, pp. 59–65, 2011.
- [70] Y. Nakamura, K. Yamamoto, X. He et al., “Wwp2 is essential for palatogenesis mediated by the interaction between Sox9 and mediator subunit 25,” *Nature Communications*, vol. 2, no. 1, p. 251, 2011.
- [71] W. Zhu, X. He, Y. Hua, Q. Li, J. Wang, and X. Gan, “The E3 ubiquitin ligase WWP2 facilitates RUNX2 protein transactivation in a mono-ubiquitination manner during osteogenic differentiation,” *The Journal of Biological Chemistry*, vol. 292, no. 27, pp. 11178–11188, 2017.
- [72] P. L. Vaddavalli and B. Schumacher, “The p53 network: cellular and systemic DNA damage responses in cancer and aging,” *Trends in Genetics*, vol. 38, no. 6, pp. 598–612, 2022.

- [73] M. Wade, Y. C. Li, and G. M. Wahl, "MDM2, MDMX and p53 in oncogenesis and cancer therapy," *Nature Reviews. Cancer*, vol. 13, no. 2, pp. 83–96, 2013.
- [74] G. P. Zambetti, E. M. Horwitz, and E. Schipani, "Skeletons in the p53 tumor suppressor closet: genetic evidence that p53 blocks bone differentiation and development," *The Journal of Cell Biology*, vol. 172, no. 6, pp. 795–797, 2006.
- [75] X. Wang, H. Y. Kua, Y. Hu et al., "p53 functions as a negative regulator of osteoblastogenesis, osteoblast-dependent osteoclastogenesis, and bone remodeling," *The Journal of Cell Biology*, vol. 172, no. 1, pp. 115–125, 2006.
- [76] C. J. Lengner, H. A. Steinman, J. Gagnon et al., "Osteoblast differentiation and skeletal development are regulated by Mdm2-p53 signaling," *The Journal of Cell Biology*, vol. 172, no. 6, pp. 909–921, 2006.
- [77] H. Zheng, G. Yang, J. Fu, Z. Chen, and G. Yuan, "Mdm2 promotes odontoblast-like differentiation by ubiquitinating Dlx3 and p53," *Journal of Dental Research*, vol. 99, no. 3, pp. 320–328, 2020.
- [78] Z. Cai, A. Moten, D. Peng et al., "The Skp2 pathway: a critical target for cancer therapy," *Seminars in Cancer Biology*, vol. 67, Part 2, pp. 16–33, 2020.
- [79] T. Bashir and M. Pagano, "Don't skip the G1 phase: how APC/CCdh1 keeps SCFSKP2 in check," *Cell Cycle*, vol. 3, no. 7, pp. 850–852, 2004.
- [80] G. Thacker, Y. Kumar, M. P. Khan et al., "Skp2 inhibits osteogenesis by promoting ubiquitin-proteasome degradation of Runx2," *Biochimica et Biophysica Acta*, vol. 1863, no. 4, pp. 510–519, 2016.
- [81] Q. Yin, C. J. Wyatt, T. Han, K. S. M. Smalley, and L. Wan, "ITCH as a potential therapeutic target in human cancers," *Seminars in Cancer Biology*, vol. 67, Part 2, pp. 117–130, 2020.
- [82] N. Shembade, N. S. Harhaj, K. Parvatiyar et al., "The E3 ligase Itch negatively regulates inflammatory signaling pathways by controlling the function of the ubiquitin-editing enzyme A20," *Nature Immunology*, vol. 9, no. 3, pp. 254–262, 2008.
- [83] M. Tao, P. C. Scacheri, J. M. Marinis, E. W. Harhaj, L. E. Matesic, and D. W. Abbott, "ITCH K63-ubiquitinates the NOD2 binding protein, RIP2, to influence inflammatory signaling pathways," *Current Biology*, vol. 19, no. 15, pp. 1255–1263, 2009.
- [84] H. Zhang and L. Xing, "Ubiquitin e3 ligase itch negatively regulates osteoblast differentiation from mesenchymal progenitor cells," *Stem Cells*, vol. 31, no. 8, pp. 1574–1583, 2013.
- [85] L. Qiu, C. Joazeiro, N. Fang et al., "Recognition and Ubiquitination of Notch by Itch, a Hect-type E3 Ubiquitin Ligase," *The Journal of Biological Chemistry*, vol. 275, no. 46, pp. 35734–35737, 2000.
- [86] C. R. Schünemann, M. Heuser, A. Ganser, and C. V. Rathinam, "The E3 ligase Itch is a regulator of bone marrow mesenchymal stem cells and the hematopoietic stem cell niche," *Blood*, vol. 130, Supplement 1, pp. 1158–1158, 2017.
- [87] H. Zhang, C. Wu, L. E. Matesic et al., "Ubiquitin E3 Ligase Itch Negatively Regulates Osteoclast Formation by Promoting Deubiquitination of Tumor Necrosis Factor (TNF) Receptor-associated Factor 6," *The Journal of Biological Chemistry*, vol. 288, no. 31, pp. 22359–22368, 2013.
- [88] S. Li, B. Shu, Y. Zhang et al., "Carboxyl terminus of Hsp70-interacting protein regulation of osteoclast formation in mice through promotion of tumor necrosis factor receptor-associated factor 6 protein degradation," *Arthritis & Rheumatology*, vol. 66, no. 7, pp. 1854–1863, 2014.
- [89] T. Wang, S. Li, D. Yi et al., "CHIP regulates bone mass by targeting multiple TRAF family members in bone marrow stromal cells," *Bone Research*, vol. 6, no. 1, p. 10, 2018.
- [90] B. Mohapatra, G. Ahmad, S. Nadeau et al., "Protein tyrosine kinase regulation by ubiquitination: Critical roles of Cbl-family ubiquitin ligases," *Biochimica et Biophysica Acta*, vol. 1833, no. 1, pp. 122–139, 2013.
- [91] T. Brennan, N. S. Adapala, M. F. Barbe, V. Yingling, and A. Sanjay, "Abrogation of Cbl-PI3K interaction increases bone formation and osteoblast proliferation," *Calcified Tissue International*, vol. 89, no. 5, pp. 396–410, 2011.
- [92] H. Guenou, K. Kaabeche, C. Dufour, H. Miraoui, and P. J. Marie, "Down-regulation of ubiquitin ligase Cbl induced by twist haploinsufficiency in Saethre-Chotzen syndrome results in increased PI3K/Akt signaling and osteoblast proliferation," *The American Journal of Pathology*, vol. 169, no. 4, pp. 1303–1311, 2006.
- [93] H. Fu, B. Doll, T. Mcnelis, and J. O. Hollinger, "Osteoblast differentiation in vitro and in vivo promoted by Osterix," *Journal of Biomedical Materials Research. Part A*, vol. 83, no. 3, pp. 770–778, 2007.
- [94] Y. H. Choi, Y. Han, S. H. Lee et al., "Cbl-b and c-Cbl negatively regulate osteoblast differentiation by enhancing ubiquitination and degradation of Osterix," *Bone*, vol. 75, pp. 201–209, 2015.
- [95] N. Suzue, T. Nikawa, Y. Onishi et al., "Ubiquitin ligase Cbl-b downregulates bone formation through suppression of IGF-I signaling in osteoblasts during denervation," *Journal of Bone and Mineral Research*, vol. 21, no. 5, pp. 722–734, 2006.
- [96] J. Creff and A. Besson, "Functional versatility of the CDK inhibitor p57Kip2," *Frontiers in Cell and Development Biology*, vol. 8, article 584590, 2020.
- [97] M. Kim, T. Nakamoto, S. Nishimori, K. Tanaka, and T. Chiba, "A new ubiquitin ligase involved in p57KIP2 proteolysis regulates osteoblast cell differentiation," *EMBO Reports*, vol. 9, no. 9, pp. 878–884, 2008.
- [98] J. Regan and F. Long, "Notch signaling and bone Remodeling," *Current Osteoporosis Reports*, vol. 11, no. 2, pp. 126–129, 2013.
- [99] J. Zhou, T. Fujiwara, S. Ye, X. Li, and H. Zhao, "Ubiquitin E3 ligase LNX2 is critical for osteoclastogenesis in vitro by regulating M-CSF/RANKL signaling and Notch2," *Calcified Tissue International*, vol. 96, no. 5, pp. 465–475, 2015.
- [100] B. E. Riley, J. C. Loughheed, K. Callaway et al., "Structure and function of Parkin E3 ubiquitin ligase reveals aspects of RING and HECT ligases," *Nature Communications*, vol. 4, no. 1, p. 4, 2013.
- [101] A. M. Pickrell and R. J. Youle, "The roles of PINK1, Parkin, and mitochondrial fidelity in Parkinson's disease," *Neuron*, vol. 85, no. 2, pp. 257–273, 2015.
- [102] M. Y. Ansari, N. M. Khan, I. Ahmad, and T. M. Haqqi, "Parkin clearance of dysfunctional mitochondria regulates ROS levels and increases survival of human chondrocytes," *Osteoarthritis and Cartilage*, vol. 26, no. 8, pp. 1087–1097, 2018.
- [103] W. Zhang, W. Hou, M. Chen et al., "Upregulation of Parkin accelerates osteoblastic differentiation of bone marrow-derived mesenchymal stem cells and bone regeneration by enhancing autophagy and β -catenin signaling," *Frontiers in Cell and Development Biology*, vol. 8, article 576104, 2020.

- [104] W. Zhao, W. Zhang, H. Ma, and M. Yang, "NIPA2 regulates osteoblast function by modulating mitophagy in type 2 diabetes osteoporosis," *Scientific Reports*, vol. 10, no. 1, p. 3078, 2020.
- [105] Y. Tsubakihara, A. Hikita, S. Yamamoto et al., "Arkadia enhances BMP signalling through ubiquitylation and degradation of Smad6," *Journal of Biochemistry*, vol. 158, no. 1, pp. 61–71, 2015.
- [106] M. Zangari, E. Terpos, F. Zhan, and G. Tricot, "Impact of bortezomib on bone health in myeloma: a review of current evidence," *Cancer Treatment Reviews*, vol. 38, no. 8, pp. 968–980, 2012.
- [107] A. Pennisi, X. Li, W. Ling, S. Khan, M. Zangari, and S. Yaccoby, "The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo," *American Journal of Hematology*, vol. 84, no. 1, pp. 6–14, 2009.
- [108] I. R. Garrett, D. Chen, G. Gutierrez et al., "Selective inhibitors of the osteoblast proteasome stimulate bone formation in vivo and in vitro," *The Journal of Clinical Investigation*, vol. 111, no. 11, pp. 1771–1782, 2003.
- [109] E. Terpos, D. J. Heath, A. Rahemtulla et al., "Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor- κ B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma," *British Journal of Haematology*, vol. 135, no. 5, pp. 688–692, 2006.
- [110] I. Zavrski, H. Krebbel, B. Wildemann et al., "Proteasome inhibitors abrogate osteoclast differentiation and osteoclast function," *Biochemical and Biophysical Research Communications*, vol. 333, no. 1, pp. 200–205, 2005.
- [111] M. A. Hurchla, A. Garcia-Gomez, M. C. Hornick et al., "The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects," *Leukemia*, vol. 27, no. 2, pp. 430–440, 2013.
- [112] Y. Ding, Y. Cui, X. Yang et al., "Anti-RANKL monoclonal antibody and bortezomib prevent mechanical unloading-induced bone loss," *Journal of Bone and Mineral Metabolism*, vol. 39, no. 6, pp. 974–983, 2021.
- [113] S. H. Kim, M. O. Kim, H. J. Kim et al., "Bortezomib prevents ovariectomy-induced osteoporosis in mice by inhibiting osteoclast differentiation," *Journal of Bone and Mineral Metabolism*, vol. 36, no. 5, pp. 537–546, 2018.
- [114] Y. Liu, X. Huang, X. He et al., "A novel effect of thalidomide and its analogs: suppression of cereblon ubiquitination enhances ubiquitin ligase function," *The FASEB Journal*, vol. 29, no. 12, pp. 4829–4839, 2015.
- [115] I. Kaczmarczyk-Sedlak, M. Zych, K. Rotko, and L. Sedlak, "Effects of thalidomide on the development of bone damage caused by prednisolone in rats," *Pharmacological Reports*, vol. 64, no. 2, pp. 386–395, 2012.
- [116] I. Kaczmarczyk-Sedlak, J. Folwarczna, and H. I. Trzeciak, "Thalidomide affects the skeletal system of ovariectomized rats," *Pharmacological Reports*, vol. 61, no. 3, pp. 529–538, 2009.
- [117] K. Mishima, H. Kitoh, B. Ohkawara et al., "Lansoprazole upregulates polyubiquitination of the TNF receptor-associated factor 6 and facilitates Runx2-mediated osteoblastogenesis," *eBioMedicine*, vol. 2, no. 12, pp. 2046–2061, 2015.
- [118] S. Birtić, P. Dussort, F. X. Pierre, A. C. Bily, and M. Roller, "Carnosic acid," *Phytochemistry*, vol. 115, pp. 9–19, 2015.
- [119] Z. G. Zheng, H. M. Cheng, Y. P. Zhou et al., "Dual targeting of SREBP2 and ERR α by carnosic acid suppresses RANKL-mediated osteoclastogenesis and prevents ovariectomy-induced bone loss," *Cell Death and Differentiation*, vol. 27, no. 7, pp. 2048–2065, 2020.
- [120] C. Lian, Z. Wu, B. Gao et al., "Melatonin reversed tumor necrosis factor-alpha-inhibited osteogenesis of human mesenchymal stem cells by stabilizing SMAD1 protein," *Journal of Pineal Research*, vol. 61, no. 3, pp. 317–327, 2016.
- [121] X. Li, W. Sun, J. Li et al., "Clomipramine causes osteoporosis by promoting osteoclastogenesis via E3 ligase Itch, which is prevented by Zoledronic acid," *Scientific Reports*, vol. 7, no. 1, article 41358, 2017.
- [122] H. L. Zheng, W. N. Xu, W. S. Zhou et al., "Beraprost ameliorates postmenopausal osteoporosis by regulating Nedd4-induced Runx2 ubiquitination," *Cell Death & Disease*, vol. 12, no. 5, p. 497, 2021.
- [123] W. F. Chiou, Y. L. Huang, and Y. W. Liu, "(+)-Vitisin A inhibits osteoclast differentiation by preventing TRAF6 ubiquitination and TRAF6-TAK1 formation to suppress NFATc1 activation," *PLoS One*, vol. 9, no. 2, article e89159, 2014.
- [124] G. Laplante and W. Zhang, "Targeting the ubiquitin-proteasome system for cancer therapeutics by small-molecule Inhibitors," *Cancers*, vol. 13, no. 12, p. 3079, 2021.
- [125] L. Deng, T. Meng, L. Chen, W. Wei, and P. Wang, "The role of ubiquitination in tumorigenesis and targeted drug discovery," *Signal Transduction and Targeted Therapy*, vol. 5, no. 1, p. 11, 2020.
- [126] M. Matsui and D. R. Corey, "Non-coding RNAs as drug targets," *Nature Reviews. Drug Discovery*, vol. 16, no. 3, pp. 167–179, 2017.
- [127] S. He, S. Yang, Y. Zhang et al., "LncRNA ODIR1 inhibits osteogenic differentiation of hUC-MSCs through the FBXO25/H2BK120ub/H3K4me3/OSX axis," *Cell Death & Disease*, vol. 10, no. 12, p. 947, 2019.
- [128] M. Tu, J. Tang, H. He, P. Cheng, and C. Chen, "MiR-142-5p promotes bone repair by maintaining osteoblast activity," *Journal of Bone and Mineral Metabolism*, vol. 35, no. 3, pp. 255–264, 2017.
- [129] Y. Jiang, J. Zhang, Z. Li, and G. Jia, "Bone marrow mesenchymal stem cell-derived exosomal miR-25 regulates the ubiquitination and degradation of Runx2 by SMURF1 to promote fracture healing in Mice," *Frontiers in Medicine*, vol. 7, article 577578, 2020.
- [130] Y. Huang, Y. Xu, S. Feng, P. He, B. Sheng, and J. Ni, "miR-19b enhances osteogenic differentiation of mesenchymal stem cells and promotes fracture healing through the WWP1/Smurf2-mediated KLF5/ β -catenin signaling pathway," *Experimental & Molecular Medicine*, vol. 53, no. 5, pp. 973–985, 2021.
- [131] Y. Li, J. Wang, Y. Ma, W. Du, K. Feng, and S. Wang, "miR-101-loaded exosomes secreted by bone marrow mesenchymal stem cells requires the FBXW7/HIF1 α /FOXO3 axis, facilitating osteogenic differentiation," *Journal of Cellular Physiology*, vol. 236, no. 6, pp. 4258–4272, 2021.
- [132] J. Chen, J. Q. Liang, Y. F. Zhen, L. Chang, Z. T. Zhou, and X. J. Shen, "DCAF1-targeting microRNA-3175 activates Nrf2 signaling and inhibits dexamethasone-induced oxidative injury

- in human osteoblasts,” *Cell Death & Disease*, vol. 12, no. 11, p. 1024, 2021.
- [133] J. Guo, F. Ren, Y. Wang et al., “miR-764-5p promotes osteoblast differentiation through inhibition of CHIP/STUB1 expression,” *Journal of Bone and Mineral Research*, vol. 27, no. 7, pp. 1607–1618, 2012.
- [134] Y. Wang, D. W. Malcolm, and D. S. W. Benoit, “Controlled and sustained delivery of siRNA/NPs from hydrogels expedites bone fracture healing,” *Biomaterials*, vol. 139, pp. 127–138, 2017.
- [135] G. M. Burslem and C. M. Crews, “Proteolysis-targeting chimeras as therapeutics and tools for biological discovery,” *Cell*, vol. 181, no. 1, pp. 102–114, 2020.